Kyowa Hakko Bio spotlights HMOs’ potential in Chinese and Thai markets
26 Jan 2021 | Kyowa Hakko Bio
In light of the increasing global demand for HMOs, Kyowa Hakko Bio is eyeing opportunities within the Chinese and Thai markets, despite a hazy regulatory environment. Moreover, the company is investing in a new Thai facility to expand its production capacity. Kentaro Yanashima, Research & Business Development for Kyowa Hakko Bio, tells NutritionInsight all about the promising potential of HMO’s for both infant and adult nutrition and the company’s expansion plans.
